Business Wire

ROBOSENSE

13.1.2021 20:02:36 CET | Business Wire | Press release

Share
RoboSense Announces The SOP Version Of Automotive-Grade, High-Performance, Solid-State LiDAR At CES2021

RoboSense officially announced the SOP version of the high-performance, automotive-grade, MEMS solid-state LiDAR RS-LiDAR-M1 at CES 2021. In the past five years of research and development, M1 has gone through dozens of iterations and has been presented at the CES for 4 consecutive years winning two CES Innovation Awards. Since July 2020, M1 has received a number of orders for serial production cars worldwide. It has been delivered to OEM partners in batches in December 2020, becoming the world's first mass-production-ready solid-state automotive LiDAR.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005687/en/

The development process of M1 has been finalized after completing the processes of product requirement definition, components selection, design and development, repeated verification tests and manufacturing. The SOP version’s features include:

  • The ranging capability reaches more than 150m for 10% reflectivity targets (with range up to 200 meters for detecting vehicle objects). The average resolution of M1 is 0.2°x0.2° (horizontally and vertically) with an ultra-wide field of view 120°×25° (horizontally and vertically) to create a high resolution of 0.75M pixel points per second.
  • The RS-LiDAR-M1 has reduced the minimum detection distance to less than 0.5 meters through upgrading the optical system design and signal processing system.
  • RoboSense has innovated the signal processing algorithms and optical system design, which has enabled the M1 to distinguish laser emission signals from ambient lights, without further concern of strong sunlight interference.
  • M1 uses the unique technologies to filter laser pulses from other LiDARs to prevent multiple LiDAR crosstalk.
  • The SOP version of M1 has reduced the size compared to the last version. Up to now, it is the world’s thinnest automotive LiDAR, with a size of 108mm(Depth) x 110mm(Width) x 45mm(Height) to make the integration into the vehicle body easy.
  • Power consumption is reduced to less than 15W.
  • M1 provides a series of supporting functions, including OTA firmware updating, blockage detection, smart cleaning, smart heating, performance detection, power management, network management, etc.
  • RoboSense strictly abides by the ISO26262 safety standard, and has integrated the fail-safe concept and technology from aerospace and rail transportation systems, achieving all-round monitoring of various system modules such as laser emitter and receiver, MEMS control, point cloud processing and transmitting, etc. Its safety mechanism has covered thousands of failure modes, fully achieving the requirements of ASIL-B and SIL-2.
  • RoboSense has adopted VDA6.3 as the basis of project management and control, fully implemented the requirements of IATF16949 quality management system and ISO26262 standard, and has integrated ISO16750 and other automotive-grade reliability specifications, to carry out a series of verification tests on M1, including random mechanical vibration, mechanical shock, splash water, stone impact, high and low temperature storage and operation, solar radiation, EMC, chemical corrosion, salt spray and others. The cumulative test time of all M1 test samples has exceeded 300,000 hours, the longest-running prototype has been in continuous operation for more than 700 days, and the total road test mileage has exceeded 200,000 kilometers.

About RoboSense:

Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. http://robosense.ai/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye